Market News

Abbott Labs (ABT)

A European regulatory body plans to examine whether certain cholesterol drugs have long-term clinical benefits and one potential outcome could be their withdrawal from the market if they come up short.
The review will have implications for Abbott Laboratories and the pharmaceutical unit of Solvay SA, which Abbott is in the process of acquiring for $6.6 billion. Abbott and Solvay co-market the drugs TriCor and Trilipix, which are in a category the European regulatory body will assess.

Oct 27 · 11:16:00 AM · Source: Easy Bourse
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

LCA-Vision (LCAV)

LCA-Vision Inc., a provider of laser vision correction services under the LasikPlus® brand, today announced a third quarter loss of $19.9 million, or $1.07 per share, compared with a net loss of $4.7 million, or $0.25 per share in the year prior period Revenue was $27.6 million compared with $37.4 million during the third quarter of last year.

Oct 27 · 9:40:00 AM · Source: Company News Release
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb CEO Jim Cornelius said the company has over $1.3 billion in its coffers to finance more deals with small drug developers.
That's despite it's recent buyout of Medarex for $2.1 billion. The company will "continue to aggressively pursue acquisitions, licensing deals and other partnerships," promised Cornelius.

Oct 23 · 12:31:00 PM · Source: Fierce Biotech
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Abbott Labs (ABT)

Abbott today dedicated its new Abbott Nutrition facility at the Research Park on the University of Illinois campus.
Abbott will use the facility to research and develop nutritional products for infants through adults. The company, which operates more than 100 facilities worldwide and sells products in more than 130 countries, will initially collaborate with faculty and students in the College of Agricultural, Consumer and Environmental Sciences. The company is beginning with 11 student interns and full time management.

Oct 23 · 11:37:00 AM · Source: Reuters
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

IDEXX Laboratories (IDXX)

IDEXX Laboratories, Inc. today reported that revenues for the third quarter of 2009 were $259.1 million compared to $251.1 million for the third quarter of 2008. Organic revenue growth, as defined below, was 5%. Earnings per diluted share for the quarter ended September 30, 2009 grew 24% to $0.52 from $0.42 for the same period in the prior year.

Oct 23 · 11:30:00 AM · Source: Company News
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Gilead Sciences (GILD)

Gilead Sciences reported Q3 earnings of $0.72 per share on net income of $673 million compared to $0.52 per share on net income of $496 million in the year ago period.
Product sales increased 23 percent to a record $1.65 billion for the third quarter of 2009, compared to $1.34 billion in the third quarter of 2008. This increase in sales was driven primarily by Gilead’s antiviral franchise, including the strong growth in sales of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) and continued growth in sales of Truvada® (emtricitabine/tenofovir disoproxil fumarate), as well as the addition of Ranexa®Â (ranolazine) to our commercial portfolio.

Oct 22 · 3:06:00 PM · Source: Press Release
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb reported Q3 earnings of $0.52 per share on net income of $5.49 billion versus $0.45 per share on net income of $5.24 billion in the year ago period.
“The performance in the third quarter of 2009 clearly shows the results of our outstanding business performance, disciplined financial management and overall strategic execution,” said James M. Cornelius, chairman and chief executive officer.

Oct 22 · 11:37:00 AM · Source: Press Release
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Amgen (AMGN)

Amgen reported Q3 earnings of $1.49 on net income of $1.5 billion versus $1.23 on net income of $1.3 billion in the year ago period. Total revenue decreased 2% during the quarter to $3.8 billion.
"Our third quarter results reflect the continued stability of our core businesses in the face of increased competition," said Kevin Sharer, chairman & chief executive officer. "We are pleased by the results of clinical studies for denosumab and Vectibix that we recently presented at a scientific meeting, and look forward to making these innovative medicines available to patients in their respective indications."

Oct 22 · 10:47:00 AM · Source: Press Release
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Previous · Next